Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Dynamic modeling of chronic myeloid leukemia response to bcr-abl1 tyrosine kinase inhibitors

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: NOH, Hayeon (College of Pharmacy, Yonsei University, Department of Pharmacy, Incheon, Korea, Republic Of)
  • Co-author(s): Hayeon Noh: Department of Pharmacy, College of Pharmacy, Yonsei University, Incheon, Korea, Republic Of
    Soo-Young Choi: Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea, Republic Of
    Hye-Young Song: Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea, Republic Of
    Soo-Hyun Kim: Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea, Republic Of
    Su Young Jung: Department of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Korea, Republic Of;, Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea, Republic Of
    Seungwon Yang: Department of Pharmacy, College of Pharmacy, Yonsei University, Incheon, Korea, Republic Of
    Won-Sik Lee: Department of Internal Medicine, Inje University College of Medicine, Inje University Busan Paik Hospital, Busan, Korea, Republic Of
    Hyeong-Joon Kim: Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic Of
    Jee Hyun Kong: Department of Hematology-Oncology, Wonju College of Medicine, Yonsei University, Wonju, Korea, Republic Of
    Hawk Kim: Department of Hematology, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic Of
    Young Rok Do: Division of Hematology-Oncology, Keimyung University, School of Medicine, Keimyung University Hospital, Daegu, Korea, Republic Of
    Jae-Yong Kwak: Division of Hematology-Oncology, Chonbuk National University Medical School, Chonbuk National University Hospital, Jeonju, Korea, Republic Of
    Sukjoong Oh: Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Sungkyunkwan University, Kangbuk Samsung Hospital, Seoul, Korea, Republic Of
    Sung Hyun Kim: Department of Internal Medicine, Dong-A University College of Medicine, Dong-A University Hospital, Busan, Korea, Republic Of
    Jeong-A Kim: Department of Hematology, The Catholic University of Korea, St. Vincent’s Hospital, Suwon, Korea, Republic Of
    Dae Young Zang: Department of Internal Medicine, Hallym University College of Medicine, Hallym University Hospital, Anyang, Korea, Republic Of
    Yeung-Chul Mun: Department of Hematology, School of Medicine, Ewha Womans University, Ewha Womans University Hospital, Seoul, Korea, Republic Of
    Young-Woong Won: Division of Hematology and Oncology, Department of Internal Medicine, Hanyang University College of Medicine, Hanyang University Guri Hospital, Guri, Korea, Republic Of
    Sung-Eun Lee: Department of Hematology, Seoul St. Mary’s Hospital, Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea, Republic Of
    Dong-Wook Kim: Department of Hematology, Seoul St. Mary’s Hospital, Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea, Republic Of
    Jangik Lee: Department of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Korea, Republic Of;, Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea, Republic Of
  • Abstract:

    Background

    A BCR-ABL1 transcript level at 3 months after the initiation of imatinib has shown to predict the long-term clinical outcomes in patients with chronic myeloid leukemia in chronic phase (CP-CML). The levels obtained earlier than 3 months may also have a similar prognostic significance.

    Purpose

    To assess the value of the BCR-ABL1 transcript..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses